These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33203866)

  • 1. Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action.
    Ling A; Huang RS
    Nat Commun; 2020 Nov; 11(1):5848. PubMed ID: 33203866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Web Application for Predicting Drug Combination Efficacy Using Monotherapy Data and IDACombo.
    Xia Y; Ling AL; Zhang W; Lee A; Su MC; Gruener RF; Jena S; Huang Y; Pareek S; Shan Y; Huang RS
    J Cancer Sci Clin Ther; 2024; 7(4):253-258. PubMed ID: 38344217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated framework for identification of effective and synergistic anti-cancer drug combinations.
    Sharma A; Rani R
    J Bioinform Comput Biol; 2018 Oct; 16(5):1850017. PubMed ID: 30304987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.
    Quintanal-Villalonga A; Molina-Pinelo S; Cirauqui C; Ojeda-Márquez L; Marrugal Á; Suarez R; Conde E; Ponce-Aix S; Enguita AB; Carnero A; Ferrer I; Paz-Ares L
    J Thorac Oncol; 2019 Apr; 14(4):641-655. PubMed ID: 30639621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma.
    Zhao J; Li QQ; Zou B; Wang G; Li X; Kim JE; Cuff CF; Huang L; Reed E; Gardner K
    Int J Oncol; 2007 Aug; 31(2):241-52. PubMed ID: 17611679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
    Toner AP; McLaughlin F; Giles FJ; Sullivan FJ; O'Connell E; Carleton LA; Breen L; Dunne G; Gorman AM; Lewis JD; Glynn SA
    Br J Cancer; 2013 Oct; 109(8):2131-41. PubMed ID: 24052043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
    Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
    Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
    Bashi AC; Coker EA; Bulusu KC; Jaaks P; Crafter C; Lightfoot H; Milo M; McCarten K; Jenkins DF; van der Meer D; Lynch JT; Barthorpe S; Andersen CL; Barry ST; Beck A; Cidado J; Gordon JA; Hall C; Hall J; Mali I; Mironenko T; Mongeon K; Morris J; Richardson L; Smith PD; Tavana O; Tolley C; Thomas F; Willis BS; Yang W; O'Connor MJ; McDermott U; Critchlow SE; Drew L; Fawell SE; Mettetal JT; Garnett MJ
    Cancer Discov; 2024 May; 14(5):846-865. PubMed ID: 38456804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
    Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
    Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
    Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for advanced gastric cancer.
    Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.
    Potter DS; Galvin M; Brown S; Lallo A; Hodgkinson CL; Blackhall F; Morrow CJ; Dive C
    Mol Cancer Ther; 2016 Jun; 15(6):1248-60. PubMed ID: 27197306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.
    Yonesaka K; Kobayashi Y; Hayashi H; Chiba Y; Mitsudomi T; Nakagawa K
    Oncol Rep; 2019 Feb; 41(2):1059-1066. PubMed ID: 30483795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
    Poels KE; Schoenfeld AJ; Makhnin A; Tobi Y; Wang Y; Frisco-Cabanos H; Chakrabarti S; Shi M; Napoli C; McDonald TO; Tan W; Hata A; Weinrich SL; Yu HA; Michor F
    Nat Commun; 2021 Jun; 12(1):3697. PubMed ID: 34140482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
    Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
    Sudo M; Chin TM; Mori S; Doan NB; Said JW; Akashi M; Koeffler HP
    Cancer Chemother Pharmacol; 2013 May; 71(5):1325-34. PubMed ID: 23515752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
    Stamelos VA; Robinson E; Redman CW; Richardson A
    Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.